Tuttle Capital Management’s Cardlytics CDLX Stock Holding History

Tuttle Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-187	Closed	-$205K	–	274
2021 Q1	$205K	Buy	+187	New	+$247K	0.08%	224

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Tuttle Capital Management's CDLX Position: Q2 2021 in Review

Tuttle Capital Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 187 shares — an estimated $205K sold.

Tuttle Capital Management first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $205K in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

Tuttle Capital Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
Tuttle Capital Management sold 187 Cardlytics shares in Q2 2021, an estimated $205K.
Tuttle Capital Management first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
Tuttle Capital Management's Cardlytics position peaked at $205K in Q1 2021.
189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Tuttle Capital Management's 13F filing for Q2 2021, filed 21 Jul 2021.